Prolonged remission in a case of Richter's transformation of B-cell chronic lymphocytic leukaemia following adoptive immunotherapy.
Milojković
D
D
Aldouri
M
M
Pagliuca
A
A
Mufti
G J
GJ
Devereux
S
S
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002330:Carmustine; D002471:Cell Transformation, Neoplastic; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine; D004317:Doxorubicin / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000473:pathology / Q000628:therapy*; D017710:Lymphocyte Transfusion / Q000379:methods; D008558:Melphalan; D011034:Podophyllotoxin; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction / Q000379:methods; D000069283:Rituximab; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D003561:Cytarabine; D000074323:Alemtuzumab; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011034:Podophyllotoxin; D008558:Melphalan; D002330:Carmustine; D011241:Prednisone